Navigation Links
Juventas Therapeutics Demonstrates JVS-100 Delivery to Patients with Heart Failure is Safe and Provides Clinical Benefit
Date:5/24/2011

CLEVELAND, May 24, 2011 /PRNewswire/ -- Juventas Therapeutics is a privately-held, clinical-stage company developing novel regenerative therapies for treatment of cardiovascular disease.  The Company's lead product, JVS-100, encodes Stromal cell-Derived Factor 1 (SDF-1) which has been shown to repair damaged tissue through recruitment of circulating stem cells to the site of injury, prevention of ongoing cell death and restoration of blood flow.  Juventas recently presented the results from its Phase I heart failure trial at the 14th Annual Meeting of the American Society of Gene and Cell Therapy.

The 17-person, open-label, dose-escalation study targeted New York Heart Association (NYHA) class III heart failure patients. Class III patients represent approximately a quarter of the 6 million heart failure patients in the United States and account for half of all heart failure hospital admissions.

"We wanted to target truly sick patients for whom there are currently no real therapeutic options," states Marc Penn, M.D., Ph.D., scientific founder and Chief Medical Officer for Juventas.  "These patients tend to have a rapidly deteriorating quality of life and the potential to provide clinical benefit is meaningful."

The clinical trial met its safety endpoints and JVS-100 was well-tolerated by all patients at all doses tested.  At four months post-treatment, patients in the targeted therapeutic dose range, are showing clinically-relevant and statistically-significant median improvements of 36 meters for 6 minute walk distance (6MWD) and 22 points in the Minnesota Living with Heart Failure Questionnaire (MLHFQ).  Nearly half of the patients improved a full NYHA heart class and, importantly, no patients worsened in heart class. Echocardiographs demonstrated that the patients' cardiac function stabilized with dose-dependent trends toward improvement in left ventricular end systolic volume (LVESV) and left ventricular ejection fraction (LVEF).

"While the focus of the trial was safety, it is encouraging to see such robust clinical benefit in the treated patients," states Douglas Losordo, M.D., principal investigator for the trial and Director of the Feinberg Cardiovascular Research Institute at the Northwestern University School of Medicine.  "These are exciting results for the cardiovascular regenerative medicine field."

Patients in the trial were also enrolled at Cardiology, P.C. (Birmingham, AL) , Rush University Medical Center (Chicago, IL), and Columbia University Medical Center(New York, NY).

"We're very pleased with the outcome of this study, which builds on more than ten years of research surrounding SDF-1, its role in stem cell homing and tissue repair," indicates Rahul Aras, Ph.D., President & Chief Executive Officer for Juventas.  "We believe JVS-100 provides a clinically attractive means through which to provide regenerative therapy without the complexity often associated with cell therapy.  It has the potential to simplify the treatment paradigm for both the physician and patient."

About Juventas Therapeutics

Juventas Therapeutics, headquartered in Cleveland, OH, is a privately-held clinical-stage biotechnology company developing a pipeline of regenerative therapies to treat life–threatening diseases. Founded in 2007 with an exclusive license from the Cleveland Clinic, Juventas has transitioned its therapeutic platform from concept to initiation of mid-stage clinical trials.  Investors include Triathlon Medical Venture Partners, Early Stage Partners, Fletcher Spaght Ventures, Reservoir Venture Partners, North Coast Angel Fund, X Gen Ltd., JumpStart Inc., and Blue Chip Venture Co. The company has received non-dilutive grant support through the Ohio Third Frontier funded Cleveland Clinic Ohio BioValidation Fund, Global Cardiovascular Innovation Center and Center for Stem Cell & Regenerative Medicine.

About JVS-100

 The company's lead product, JVS-100 encodes Stromal–cell Derived Factor 1 (SDF–1).  SDF-1 promotes tissue repair through recruitment of endogenous stem cells to the damaged organ, promotion of new blood vessel formation and prevention of ongoing cell death.  The SDF-1 repair pathway is well-conserved in a broad range of end organ systems, including the heart, vasculature, dermis, kidney, and eye.  JVS-100 is currently being clinically evaluated for treatment of heart failure and late stage peripheral vascular disease and has been shown to protect and repair tissue following organ–damage in a broad range of pre–clinical disease models. 

Website: www.juventasinc.com


'/>"/>
SOURCE Juventas Therapeutics, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related biology technology :

1. Juventas Therapeutics Initiating Phase II Clinical Trial of JVS-100 for Treatment of Critical Limb Ischemia
2. Northwest Biotherapeutics to Present at American Society of Cell and Gene Therapy
3. Northwest Biotherapeutics and the Fraunhofer Institute for Cell Therapy and Immunology are Partnering for Clinical Trials and Compassionate Use Cases in Europe
4. Nile Therapeutics to Transition to OTCQB Marketplace
5. Halozyme Therapeutics Reports First Quarter 2011 Financial Results
6. InVivo Therapeutics and The Miami Project to Cure Paralysis Form Strategic Research Collaboration to Develop Novel Treatments for Spinal Cord Injuries
7. Talecris Biotherapeutics Announces Results of Annual Stockholders Meeting
8. Silence Therapeutics Issued Japanese Patent Covering its Core RNA Interference (RNAi) Technology
9. Cell Therapeutics Retires 7.5% Convertible Senior Notes
10. Talecris Biotherapeutics Announces First Quarter 2011 Results
11. Nektar Therapeutics Reports First Quarter 2011 Financial Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/11/2017)... a leading provider of patient support solutions, has announced the ... which will launch this week. The VMS CNEs will address ... enhance the patient care experience by delivering peer-to-peer education programs ... to help women who have been diagnosed and are being ... ...
(Date:10/11/2017)... ... October 11, 2017 , ... ... granted orphan drug designation to SBT-100, its novel anti-STAT3 (Signal Transducer and Activator ... osteosarcoma. SBT-100 is able to cross the cell membrane and bind intracellular STAT3 ...
(Date:10/10/2017)... ... 2017 , ... Dr. Bob Harman, founder and CEO of VetStem Biopharma, ... The event entitled “Stem Cells and Their Regenerative Powers,” was held on ... DVM, MPVM was joined by two human doctors: Peter B. Hanson, M.D., Chief of ...
(Date:10/10/2017)... , ... October 10, 2017 , ... ... of 13 prestigious awards honoring scientists who have made outstanding ... a scheduled symposium during Pittcon 2018, the world’s leading conference and exposition for ...
Breaking Biology Technology:
(Date:8/15/2017)... Aug. 15 2017   ivWatch LLC , a medical device ... therapy, today announced receipt of its ISO 13485 Certification, the global ... International Organization for Standardization (ISO®). ... ivWatch Model 400 Continuous Monitoring device for the early detection of ... "This is an important milestone ...
(Date:6/23/2017)... ITHACA, N.Y. , June 23, 2017 /PRNewswire/ ... leader in dairy research, today announced a new collaboration ... reduce the chances that the global milk supply is ... dairy project, Cornell University has become the newest academic ... Supply Chain, a food safety initiative that includes IBM ...
(Date:5/16/2017)... N.J. , May 16, 2017  Veratad Technologies, ... provider of online age and identity verification solutions, announced ... K(NO)W Identity Conference 2017, May 15 thru May 17, ... Regan Building and International Trade Center. ... the globe and in today,s quickly evolving digital world, ...
Breaking Biology News(10 mins):